Cancer Vaccine Trial Cuts Melanoma Deaths by Half

A groundbreaking personalized cancer vaccine has reduced the risk of melanoma relapse or death by 49% in a major trial.

Scientists say this approach could transform treatment for several cancer types within the next few years.